Literature DB >> 3941500

The economic impact of the first 10,000 cases of acquired immunodeficiency syndrome in the United States.

A M Hardy, K Rauch, D Echenberg, W M Morgan, J W Curran.   

Abstract

Acquired immunodeficiency syndrome (AIDS) is a serious, fatal disease affecting a relatively young population and has a great economic impact. Expenditures for hospitalization and economic losses from disability and premature death were estimated for the first 10,000 patients with AIDS reported in the United States. Extrapolation of data from surveys done in New York City, Philadelphia, and San Francisco suggests that these 10,000 patients with AIDS will require an estimated 1.6 million days in the hospital, resulting in over $1.4 billion in expenditures. Losses incurred for the 8,387 years of work that will be lost from disability and from the premature death of the 10,000 patients will be over $4.8 billion. The total economic burden of the AIDS epidemic will continue to rise as the number of diagnosed cases increases. These estimates reinforce the need for effective disease prevention strategies to reduce the number of cases.

Entities:  

Mesh:

Year:  1986        PMID: 3941500

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  31 in total

1.  A survival analysis of hospitalization among patients with acquired immunodeficiency syndrome.

Authors:  C P Quesenberry; B Fireman; R A Hiatt; J V Selby
Journal:  Am J Public Health       Date:  1989-12       Impact factor: 9.308

Review 2.  Economic models of antiretroviral therapy: searching for the optimal strategy.

Authors:  Fred J Hellinger
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

3.  The acquired immune deficiency syndrome and epidemic of infection with human immunodeficiency virus: costs of care and prevention in an inner London district.

Authors:  A M Johnson; M W Adler; J M Crown
Journal:  Br Med J (Clin Res Ed)       Date:  1986-08-23

4.  Estimating the mortality cost of AIDS: do estimates of earnings differ?

Authors:  C E Begley; M M Crane; G Perdue
Journal:  Am J Public Health       Date:  1990-10       Impact factor: 9.308

5.  Care for patients with HIV infection and AIDS.

Authors:  M W Adler
Journal:  Br Med J (Clin Res Ed)       Date:  1987-07-04

6.  The pharmacoeconomics of HIV disease.

Authors:  L A Lynn; K A Schulman; J M Eisenberg
Journal:  Pharmacoeconomics       Date:  1992-03       Impact factor: 4.981

Review 7.  AIDS in New York City: the role of intravenous drug users.

Authors:  A Ron; D E Rogers
Journal:  Bull N Y Acad Med       Date:  1989-09

8.  Evaluation of drug use and cost of hospital care for AIDS patients between 1990 and 1994.

Authors:  F Peyron; A Flori; S Galliano-di Bernardo Bernardo; J Moreau; M Buès-Charbit; G Balansard
Journal:  Pharm World Sci       Date:  1997-08

9.  Effect of changing patterns of care and duration of survival on the cost of treating the acquired immunodeficiency syndrome (AIDS).

Authors:  G R Seage; S Landers; G A Lamb; A M Epstein
Journal:  Am J Public Health       Date:  1990-07       Impact factor: 9.308

Review 10.  Defining and measuring the costs of the HIV epidemic to business firms.

Authors:  P G Farnham
Journal:  Public Health Rep       Date:  1994 May-Jun       Impact factor: 2.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.